Linaclotide (Linzess)
Overview
A synthetic 14-amino acid peptide structurally related to the heat-stable enterotoxin of Escherichia coli and the endogenous peptide guanylin. Linaclotide activates guanylate cyclase-C (GC-C) on the luminal surface of intestinal epithelium, increasing intracellular cGMP to stimulate CFTR-mediated chloride and bicarbonate secretion, accelerating intestinal transit.
Mechanism of Action
Extracellular cGMP also reduces firing of visceral afferent pain fibers, providing analgesic effects in the gut.
Research Summary & Key Findings
FDA-approved in 2012 for IBS-C and CIC. Phase 3 trials demonstrated significant improvements in bowel frequency, straining, abdominal pain, and bloating. Minimal systemic absorption (<0.1% bioavailability) provides a favorable safety profile. Shown to reduce abdominal pain independent of its effects on bowel function, supporting a direct visceral analgesic mechanism (Rao et al., NEJM, 2016).
Clinical Status
Linaclotide (Linzess) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Linaclotide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Linaclotide"
Registered interventional and observational studies, including status and phase.
- PubChem — "Linaclotide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Gastrointestinal
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneou...
View detailsLanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. L...
View detailsPasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly...
View detailsPlecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates f...
View detailsStart Your Consultation
Get an AI-proposed Linaclotide (Linzess) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Linaclotide (Linzess).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.